Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 75 versus FLOVENT HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 75 versus FLOVENT HFA.
DEXONE 0.75 vs FLOVENT HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduce inflammation, immune response, and adrenal function.
Fluticasone propionate is a synthetic corticosteroid that binds to glucocorticoid receptors, increasing the synthesis of lipocortins, which inhibit phospholipase A2, thereby reducing arachidonic acid release and decreasing prostaglandin and leukotriene production. It also suppresses inflammatory cell migration and cytokine release, leading to reduced airway inflammation and hyperreactivity.
0.75 mg orally once daily, typically as part of a tapering regimen for anti-inflammatory or immunosuppressive effects.
Adult: 88-880 mcg twice daily via oral inhalation; typical starting dose: 88 mcg twice daily for patients previously on bronchodilators alone, 220 mcg twice daily for patients on inhaled corticosteroids.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours in adults with normal renal function; prolonged to 72-168 hours in severe renal impairment.
Terminal elimination half-life is approximately 7.8 hours (range 6.5-10.6 hours) after inhalation, supporting twice-daily dosing.
Renal: ~65-80% as unchanged drug; Fecal: ~10-15% as metabolites; Minor biliary excretion.
Primarily fecal (approximately 60-80%) after biliary elimination, with renal excretion accounting for <5% as unchanged drug and metabolites.
Category C
Category C
Corticosteroid
Corticosteroid